# Integer Holdings Corp: Form 10-Q for the period ended Mar 30, 2018

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2018-05-04
- Accepted by EDGAR: May 4, 2018, 13:25 ET
- Period: 2018-03-30
- Accession: 0001114483-18-000014
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448318000014/form10-q2018x03x30.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448318000014/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-12-30 to 2018-03-30 | $286.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2017-12-30 to 2018-03-30 | $95.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2017-12-30 to 2018-03-30 | $41.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-12-30 to 2018-03-30 | $34.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-12-30 to 2018-03-30 | $26.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-12-30 to 2018-03-30 | $4.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-12-30 to 2018-03-30 | $8.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-12-30 to 2018-03-30 | $0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-12-30 to 2018-03-30 | $0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-12-30 to 2018-03-30 | 32,423,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2017-12-30 to 2018-03-30 | $46.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2017-12-30 to 2018-03-30 | $11.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-03-30 | $29.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-30 | $528.8m | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-30 | $2.85bn | us-gaap:Assets |
| Current liabilities | at 2018-03-30 | $224.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-30 | $1.93bn | us-gaap:Liabilities |
| Long-term debt | at 2018-03-30 | $1.53bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-03-30 | $32.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-03-30 | $920.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 52,274 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2017. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- future sales, expenses, and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
- our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our high level of indebtedness, our inability to pay principal and interest on this high level of outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; enactment related and ongoing impacts related to the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), including the Global Intangible Low-Taxed Income (“GILTI”) tax; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

- 25 -

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular and advanced surgical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principle product lines. The Medical segment includes the Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular and Cardiac & Neuromodulation product lines and the Non-Medical segment is comprised of the Electrochem product line.

### Strategic Overview

During 2017, we undertook a thorough strategic review of our customers, competitors and markets. As a result of this review, during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. These steps include focusing our investment in research and development and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. The execution of this strategy will be our primary focus going forward.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our abilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

### 2018 Outlook(a)

(dollars in millions, except per share amounts)

|  | GAAP |  | Non-GAAP(b)(c) |  |
| --- | --- | --- | --- | --- |
|  | **As Reported** | **Growth** | **Adjusted** | **Growth** |
| Sales | $1,510 to $1,550 | 3% to 6% | $1,510 to $1,550 | 3% to 6% |
| Net Income | $50 to $60 | (25%) to (10%) | $103 to $113 | 14% to 25% |
| EBITDA | N/A | N/A | $310 to $320 | 9% to 12% |
| Earnings per Diluted Share | $1.55 to $1.85 | (26%) to (11%) | $3.20 to $3.50 | 14% to 25% |

(a) Our 2018 Outlook does not reflect the potential impact of the planned divestiture of the Advanced Surgical and Orthopedics product lines that was announced on May 3, 2018. Refer to Note 16 “Subsequent Event” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the divestiture.

(b) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted Net Income, Adjusted Earnings per Diluted Share and Adjusted EBITDA, included in our “2018 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from this non-GAAP financial measure.

(c) Adjusted Net Income and EPS for 2018 is expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization, IP-related litigation costs, consolidation and realignment costs, asset disposition and write-down charges, and loss on extinguishment of debt totaling approximately $63 million. The after-tax impact of these items is estimated to be approximately $50 million, or approximately $1.54 per diluted share. Additionally, Adjusted Net Income and EPS is expected to exclude the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. net operating losses (“NOLs”), and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in approximately three to five years. This adjustment makes our Adjusted Diluted EPS more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

Adjusted EBITDA is expected to consist of Adjusted Net Income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $207 million.

- 26 -

### Financial Overview

Net income for the first quarter of 2018 was $8.1 million, or $0.25 per diluted share, compared to a net loss of $4.3 million, or $0.14 per diluted share for the first quarter of 2017. This variance is primarily the result of the following:

- Sales increased $36.3 million or 11%. Foreign currency exchange rates increased sales by approximately $6 million. Organic sales for the first quarter of 2018 increased 9%, primarily driven by sales growth in our Medical segment through strong demand for Integer-owned products in the Cardio & Vascular product line, as well as strong demand for Neuromodulation products and strength in the Advanced Surgical, Orthopedics & Portable Medical product line;
- Gross profit for the first quarter of 2018 increased $4.5 million, primarily due to the increase in sales discussed above, partially offset by price concessions given to our larger OEM customers and higher incentive compensation based upon current quarter results;
- Operating expenses for the first quarter of 2018 were lower by $3.6 million, due to a decrease in other operating expenses ($6.5 million) attributable to the completion of spending on integration activities and various efficiencies and synergies gained as a result of our integration and consolidation initiatives partially offset by higher incentive compensation ($2.3 million);
- Interest expense for the first quarter of 2018 declined $2.4 million, primarily attributable to lower outstanding debt balances due to the repayment of debt over the last year;
- Net gains on cost and equity method investments, which are unpredictable in nature, increased first quarter income by $5.4 million as a result of a net gain of $5.0 million in the first quarter of 2018 compared to a net loss of $0.4 million during the first quarter of 2017; and
- Other loss, net for the first quarter of 2018 was lower by $0.4 million (lower net loss), which includes a $0.1 million decrease in foreign currency exchange rate losses (favorable impact).
- Income tax provision increased primarily due to an increase in pre-tax income, resulting from the factors discussed above and the estimated impact of the GILTI tax.

### Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our earnings releases and investor presentations adjusted pre-tax income, adjusted net income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA and organic sales growth rates. Adjusted pre-tax income, adjusted net income and adjusted earnings per diluted share consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets including inventory step-up amortization, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) extinguishment of debt charges, (x) the income tax (benefit) related to these adjustments (not for adjusted pre-tax income) and (xi) certain tax items that are outside the normal provision for the period (not for adjusted pre-tax income). Adjusted earnings per diluted share are calculated by dividing adjusted net income by diluted weighted average shares outstanding. Adjusted EBITDA consists of GAAP net income (loss) plus (i) the same adjustments as listed above except for items (x) and (xi), (ii) GAAP stock-based compensation, interest expense, and depreciation, (iii) GAAP provision (benefit) for income taxes and (iv) cash gains received from cost and equity method investments during the period. To calculate organic sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic sales growth rates provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

- 27 -

A reconciliation of GAAP net income (loss) and diluted earnings (loss) per share (“EPS”) to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended March 30, 2018 Pre-Tax | Net Income | Per Diluted Share | March 31, 2017 Pre-Tax | Net Income (Loss) | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| As reported (GAAP) | $12,209 | $8,118 | $0.25 | $(4,195) | $(4,339) | $(0.14) |
| Adjustments: |  |  |  |  |  |  |
| Amortization of intangibles(a) | 11,713 | 9,304 | 0.29 | 10,978 | 7,746 | 0.24 |
| IP related litigation (SG&A)(a)(b) | 321 | 254 | 0.01 | 377 | 245 | 0.01 |
| Strategic reorganization and alignment (OOE)(a)(c) | 3,492 | 2,779 | 0.09 | — | — | — |
| Manufacturing alignment to support growth (OOE)(a)(d) | 513 | 369 | 0.01 | — | — | — |
| Consolidation and optimization expenses (OOE)(a)(e) | 605 | 473 | 0.01 | 2,395 | 1,899 | 0.06 |
| Acquisition and integration expenses (OOE)(a)(f) | — | — | — | 4,820 | 3,133 | 0.10 |
| Asset dispositions, severance and other (OOE)(a)(g) | 667 | 489 | 0.02 | 4,556 | 2,957 | 0.09 |
| (Gain) loss on cost and equity method investments, net(a) | (4,970) | (3,926) | (0.12) | 398 | 259 | 0.01 |
| Loss on extinguishment of debt(a)(h) | 1,057 | 835 | 0.03 | 1,559 | 1,013 | 0.03 |
| Tax adjustments(i) | — | 1,021 | 0.03 | — | — | — |
| Adjusted (Non-GAAP) | $25,607 | $19,716 | $0.61 | $20,888 | $12,913 | $0.41 |
| Diluted weighted average shares for adjusted EPS(j) |  | 32,423 |  |  | 31,685 |  |

(a) The difference between pre-tax and net income (loss) amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 21% U.S. tax rate (35% U.S. tax rate for 2017 periods), and the statutory tax rates in Mexico, Germany, France, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of NOLs. Amortization of intangibles and OOE expense have also been adjusted to reflect the estimated impact relating to our disallowed deduction of the GILTI tax, as described in note (i) below. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and again in the third quarter of 2017 that resulted in a jury awarding damages in the amount of $37.5 million. In March 2018, the court vacated that damage award and ordered a new trial on damages, which is scheduled for January 2019. To date, no gains have been recognized in connection with this litigation.

(c) As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during the first quarter of 2018 we incurred charges related to this strategy, which primarily consisted of severance and fees for professional services.

(d) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(e) During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.

(f) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015.

(g) Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.

(h) Represents debt extinguishment charges in connection with pre-payments made on our Term B Loan Facility, which are included in interest expense.

- 28 -

(i) Tax adjustments primarily includes the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. NOLs, and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in approximately three to five years. This adjustment makes our Adjusted Diluted EPS more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

(j) The diluted weighted average shares for adjusted EPS for the three month period ended March 31, 2017 includes 669,000 of potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive in that period.

Adjusted diluted EPS, which excludes the impact of amortization of intangible assets, losses on extinguishment of debt and various other operating expenses, among others, was $0.61 per share for the first quarter of 2018, compared to $0.41 per share for the first quarter of 2017. These results reflect the benefit of our increased sales, lower interest expense, and the completion of spending on integration activities, partially offset by higher incentive compensation.

A reconciliation of GAAP net income (loss) to EBITDA and adjusted EBITDA is as follows (dollars in thousands):

|  | Three Months Ended March 30, 2018 | March 31, 2017 |
| --- | ---: | ---: |
| Net income (loss) (GAAP) | $8,118 | $(4,339) |
| Interest expense | 26,445 | 28,893 |
| Provision for income taxes | 4,091 | 144 |
| Depreciation | 14,621 | 13,628 |
| Amortization | 11,713 | 10,978 |
| EBITDA | 64,988 | 49,304 |
| IP related litigation | 321 | 377 |
| Stock-based compensation (excluding OOE) | 3,218 | 2,406 |
| Strategic reorganization and alignment | 3,492 | — |
| Manufacturing alignment to support growth | 513 | — |
| Consolidation and optimization expenses | 605 | 2,395 |
| Acquisition and integration expenses | — | 4,820 |
| Asset dispositions, severance and other | 667 | 4,556 |
| Non-cash (gain) loss on cost and equity method investments | (4,970) | 398 |
| Adjusted EBITDA (Non-GAAP) | $68,834 | $64,256 |

### Our CEO’s View

We delivered another quarter of strong year-over-year sales growth, driven by strength in our Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular, and Electrochem product lines as well as a return to growth in our Cardiac & Neuromodulation product line. Cash flow generation remains strong and enabled further accelerated debt pay down in the quarter. We have increased our 2018 guidance to reflect our strong first quarter results and our confidence in continued year over year revenue growth throughout the remainder of the year.

We are pleased with our sustained quarterly growth demonstrating our progress towards transitioning our business back to a long-term growth trajectory. As we look forward, we believe we have significant opportunities to further expand and grow our business. We have a unique breadth of capabilities to serve our customers across the entire product continuum and across multiple product categories. Whether a customer needs an engineered component or a complete device that we’ve developed, or anything in between, we can deliver. Our innovative design and manufacturing capabilities, our global footprint and scalability, our high-quality, and our customer focus enable us to deliver more for our customers.

- 29 -

### Cost Savings and Consolidation Efforts

In 2018 and 2017, we recorded charges in Other Operating Expenses related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

| Initiative | Expected Expense | Expected Capital Expenditures | Expected Annual Cost Savings(a) | Expected Completion Date |
| --- | --- | --- | --- | --- |
| Strategic reorganization and alignment | $10 - $12 | - | $8 - $12 | 2018 |
| Manufacturing alignment to support growth | $9 - $11 | $4 - $6 | $2 - $3 | 2019 |
| Consolidation and optimization expenses | $18 - $22 | $5 - $6 | $12 - $13 | 2018 |

(a) Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed, some of which are already included in our current period results.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected to be incurred as we seek to create an optimized manufacturing footprint, leveraging our increased scale and product capabilities while also supporting the needs of our customers. Our efforts will include:

- potential manufacturing consolidations;
- continuous improvement;
- productivity initiatives;
- direct material and indirect expense savings opportunities; and
- the establishment of centers of excellence.

Refer to Note 7 “Other Operating Expenses” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact, and amount of future expenditures for our cost savings and consolidation initiatives.

- 30 -

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The first quarter of 2018 and 2017 ended on March 30, and March 31, respectively, and each contained 13 weeks.

The following tables present selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share):

| Medical Sales: | Three Months Ended March 30, 2018 | March 31, 2017 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $138,348 | $125,108 | $13,240 | 10.6% |
| Cardiac & Neuromodulation | 108,910 | 103,813 | 5,097 | 4.9% |
| Advanced Surgical, Orthopedics & Portable Medical | 121,775 | 105,146 | 16,629 | 15.8% |
| Total Medical Sales | 369,033 | 334,067 | 34,966 | 10.5% |
| **Non-Medical** | 12,712 | 11,346 | 1,366 | 12.0% |
| Total Sales | 381,745 | 345,413 | 36,332 | 10.5% |
| Cost of sales | 285,975 | 254,187 | 31,788 | 12.5% |
| Gross profit | 95,770 | 91,226 | 4,544 | 5.0% |
| Gross profit as a % of sales | 25.1% | 26.4% |  |  |
| SG&A | 41,238 | 39,499 | 1,739 | 4.4% |
| SG&A as a % of sales | 10.8% | 11.4% |  |  |
| RD&E | 14,538 | 13,411 | 1,127 | 8.4% |
| RD&E as a % of sales | 3.8% | 3.9% |  |  |
| Other operating expenses | 5,277 | 11,771 | (6,494) | (55.2)% |
| Operating income | 34,717 | 26,545 | 8,172 | 30.8% |
| Operating margin | 9.1% | 7.7% |  |  |
| Interest expense | 26,445 | 28,893 | (2,448) | (8.5)% |
| (Gain) loss on cost and equity method investments, net | (4,970) | 398 | (5,368) | NM |
| Other loss, net | 1,033 | 1,449 | (416) | (28.7)% |
| Income (loss) before income taxes | 12,209 | (4,195) | 16,404 | NM |
| Provision for income taxes | 4,091 | 144 | 3,947 | NM |
| Effective tax rate | 33.5% | (3.4)% |  |  |
| Net income (loss) | $8,118 | $(4,339) | $12,457 | NM |
| Net income as a % of sales | 2.1% | (1.3)% |  |  |
| Diluted earnings per share | $0.25 | $(0.14) | $0.39 | NM |

NM Calculated amount not meaningful

- 31 -

### Product Line Sales Highlights

For the first quarter of 2018, Cardio & Vascular sales increased $13.2 million, or 11% versus the comparable 2017 period. These increases were primarily driven by continued strong demand for Integer-owned products from new and existing customers and increased demand for contract manufactured products. During the first quarter of 2018, price concessions to our larger OEM customers reduced Cardio & Vascular sales by approximately $1.6 million, in comparison to the same period of 2017. Foreign currency exchange rate fluctuations increased first quarter 2018 sales by approximately $1.5 million in comparison to the 2017 period primarily due to U.S. dollar fluctuations relative to the Euro.

For the first quarter of 2018, Cardiac & Neuromodulation sales increased $5.1 million, or 5% versus the comparable 2017 period. The increase in Cardiac & Neuromodulation sales was driven by strong Neuromodulation demand and the resolution of a supply constraint in the prior year. Price concessions to our larger OEM customers reduced first quarter 2018 Cardiac & Neuromodulation sales by approximately $2.5 million, in comparison to the same period of 2017. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the first quarter of 2018 in comparison to the same period of 2017.

Advanced Surgical, Orthopedics & Portable Medical first quarter 2018 sales increased $16.6 million, or 16%, versus the comparable 2017 period. This increase was driven by volume strength with existing customers, new product ramps, and expected tailwind from customer inventory management. For the first quarter of 2018, price concessions to our larger OEM customers reduced Advanced Surgical, Orthopedics & Portable Medical sales by approximately $0.8 million, in comparison to the same period of 2017. Foreign currency exchange rate fluctuations increased first quarter 2018 sales by approximately $4.5 million in comparison to the 2017 period primarily due to U.S. dollar fluctuations relative to the Euro.

For the first quarter of 2018, Non-Medical sales increased $1.4 million, or 12%, versus the comparable 2017 period. This increase was driven by new business wins in a stable energy market. Foreign currency exchange rates and price fluctuations did not have a material impact on Non-Medical sales during the first quarter of 2018 in comparison to the same period of 2017.

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months |
| --- | ---: |
| Price(a) | (1.3)% |
| Mix(b) | (0.4) |
| Incentive compensation(c) | (0.5) |
| Production efficiencies and volume(d) | 0.9 |
| Total percentage point change to gross profit as a percentage of sales | (1.3)% |

(a) Our Gross Margin for the first quarter of 2018 has been negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments.

(b) Our Gross Margin for the first quarter of 2018 has been negatively impacted by a higher mix of sales of lower margin products.

(c) Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(d) Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for the first quarter of 2018 has been positively impacted by production efficiencies and synergies gained as a result of our integration and consolidation initiatives as well as higher volume in comparison to the respective 2017 period.

- 32 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months |
| --- | ---: |
| Legal expenses(a) | $(710) |
| Intangible asset amortization(b) | 848 |
| Incentive compensation programs(c) | 1,813 |
| Other(d) | (212) |
| Net increase in SG&A Expenses | $1,739 |

(a) Amount represents the change in legal costs compared to the prior year period, including legal expenses incurred related to our on-going patent infringement case. Refer to Note 9 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.

(b) Amount represents the increase in intangible asset amortization (i.e. customer list), which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.

(c) Amount represents the impact to our SG&A attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(d) Represents various increases and decreases to our SG&A.

### RD&E

Changes to RD&E expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months |
| --- | ---: |
| Incentive compensation programs(a) | $465 |
| Other(b) | 662 |
| Net increase in RD&E | $1,127 |

(a) Amount represents the impact to our RD&E attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(b) Represents the net impact of various increases and decreases to our RD&E. RD&E expense for the first quarter of 2018 reflects our increased investment in projects with a higher growth opportunity.

- 33 -

### Other Operating Expenses

Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 7 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses is comprised of the following (in thousands):

|  | Three Months Ended March 30, 2018 | March 31, 2017 |
| --- | ---: | ---: |
| Strategic reorganization and alignment(a) | $3,492 | $— |
| Manufacturing alignment to support growth(b) | 513 | — |
| Consolidation and optimization costs(c) | 605 | 2,395 |
| Acquisition and integration expenses(d) | — | 4,820 |
| Asset dispositions, severance and other(e) | 667 | 4,556 |
| Total other operating expenses | $5,277 | $11,771 |

(a) As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during the first quarter of 2018, we incurred charges related to this strategy, which primarily included severance and fees for professional services.

(b) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(c) During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.

(d) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015. This initiative was substantially complete as of December 29, 2017.

(e) Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. For 2018, Other Operating Expenses is expected to be approximately $10 million to $15 million. Refer to the “Cost Savings and Consolidation Efforts” section of this Item for further details on these initiatives.

### Interest Expense

Interest Expense for the quarter ended March 30, 2018 was $26.4 million, compared to $28.9 million for the quarter ended March 31, 2017. The weighted average interest rates paid on all outstanding borrowings for the quarter ended March 30, 2018 was 5.80%, compared to 5.77%, for the comparable period in 2017. The weighted average interest rates paid in the first quarter of 2018 reflect amendments of our Senior Secured Credit Facilities in March 2017 and again in November 2017, which resulted in a cumulative 100 basis point reduction to the applicable interest rate margins of our Term Loan B facility, partially offset by an increase in LIBOR during 2017 and 2018. Cash interest expense decreased $1.9 million for the quarter ended March 30, 2018, when compared to the same period in 2017, primarily due to lower outstanding debt balances due to the repayment of debt over the last year. Non-cash interest expense (i.e. deferred fee and discount amortization) decreased $0.6 million for the quarter ended March 30, 2018 when compared to the same period in 2017, primarily attributable to lower accelerated write-offs (losses from extinguishment of debt) of deferred fees and discounts due to prepayments of portions of our Term Loan B facility during the respective quarters. We recognized losses from extinguishment of debt during the quarters ended March 30, 2018 and March 31, 2017 of $1.1 million and $1.6 million, respectively. We repaid $50.0 million of debt during the first quarter of 2018. See Note 4 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

- 34 -

### (Gain) Loss on Cost and Equity Method Investments, Net

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments. During the three months ended March 30, 2018 and March 31, 2017, we recognized a net gain of $5.0 million and a net loss of $0.4 million, respectively, on our equity method investment. Our cost method investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses. See Note 12 “Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our cost and equity method investments.

### Other Loss, Net

Other Loss for the quarters ended March 30, 2018 and March 31, 2017 was $1.0 million and $1.5 million, respectively. Other Loss is primarily comprised of income (loss) from the impact of foreign currency exchange rates on transactions denominated in foreign currencies.

The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other Loss, Net for the quarters ended March 30, 2018 and March 31, 2017 were losses of $1.4 million and $1.5 million, respectively. These losses were primarily driven by the impact of the weakening U.S. dollar relative to the Euro on our inter-company loans and are primarily non-cash in nature. We continually monitor our foreign currency exposures and take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

### Provision for Income Taxes

We recognized an income tax expense of $4.1 million for the first quarter of 2018 on $12.2 million of pre-tax income compared to an income tax expense of $0.1 million on $4.2 million of pre-tax losses for the same period of 2017, which represents a worldwide effective tax rate of 33.5% and (3.4%) for the first quarter of 2018 and 2017, respectively. The 2018 estimated annual effective tax rate includes the estimated impact of the U.S. Tax Reform Act provisions.

We expect there to be continued volatility of our effective tax rate due to several factors including: changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

Our worldwide effective tax rate is expected to be approximately 34% for 2018, excluding discrete items. Our effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. We currently have NOLs to offset forecasted U.S. taxable income and as such, are temporarily subject to the deduction limitation, which correspondingly imposes an incremental impact on U.S. Income tax. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Germany, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions. Our 2018 blended effective tax rate on foreign earnings is currently estimated to be approximately 18%. The foreign rate differential reduces our worldwide effective tax rate by approximately 2% as compared to the U.S. statutory federal income tax rate. For the year, we expect to have positive income before taxes in our foreign jurisdictions but losses before taxes in U.S. jurisdictions due to our projected amount of Interest Expense.

- 35 -

### Liquidity and Capital Resources

*(dollars in thousands)*

|  | March 30, 2018 | December 29, 2017 |
| --- | ---: | ---: |
| Cash and cash equivalents | $29,488 | $44,096 |
| Working capital | 304,035 | 322,906 |
| Current ratio | 2.35 | 2.54 |

Cash and cash equivalents at March 30, 2018 decreased by $14.6 million from year-end as excess cash flow from operations was used to pay down our debt. Working capital decreased $18.9 million from December 29, 2017 due to the Company’s strategic initiatives to reduce working capital in order to generate cash to pay down debt.

At March 30, 2018, $21 million of our cash and cash equivalents were held by foreign subsidiaries. As a result of the Tax Reform Act, we changed our permanent reinvestment assertion related to previously undistributed foreign earnings. Going forward, we intend to limit our distributions from foreign subsidiaries to previously taxed income. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

### Summary of Cash Flow

*(in thousands)*

| Cash provided by (used in): | Three Months Ended March 30, 2018 | March 31, 2017 |
| --- | ---: | ---: |
| Operating activities | $46,122 | $38,625 |
| Investing activities | (10,061) | (12,588) |
| Financing activities | (51,214) | (23,491) |
| Effect of foreign currency exchange rates on cash and cash equivalents | 545 | 219 |
| Net change in cash and cash equivalents | $(14,608) | $2,765 |

***Operating Activities –*** During the quarter ended March 30, 2018, we generated cash of $46.1 million from operations compared to $38.6 million for the quarter ended March 31, 2017. This increase was primarily due to a $10.8 million increase in cash net income (i.e. net income plus adjustments to reconcile net income (loss) to net cash provided by operating activities), partially offset by a $3.3 million decrease in cash flow provided by working capital. Other non-cash gains reported in cash flows from operating activities increased $6.3 million primarily due to non-cash equity method investment gains.

***Investing Activities –*** The $2.5 million decrease in net cash used in investing activities was primarily attributable to lower purchases of property, plant, and equipment. Our current expectation is that capital spending for 2018 will be in the range of $50 million to $55 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures.

***Financing Activities –*** Net cash used in financing activities for the first quarter of 2018 was $51.2 million compared to $23.5 million in the comparable 2017 period. Financing activities during the first quarter of 2018 included net payments of $50.0 million related to paying down our debt obligations, which included prepayments of $43.0 million on our Term Loan B facility.

***Capital Structure –*** As of March 30, 2018, our capital structure consists of $1.6 billion of debt outstanding under our Senior Secured Credit Facilities and Senior Notes and 32 million shares of common stock outstanding. If necessary, as of March 30, 2018, we had access to $116.8 million of borrowing capacity under our Revolving Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts our covenant calculations. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of March 30, 2018, our debt service obligations, comprised of principal and interest payments for the remainder of 2018, are estimated to be approximately $97 million.

- 36 -

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under the Revolving Credit Facility should be sufficient to meet our working capital and fixed capital requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

***Credit Facilities*** - As of March 30, 2018, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had $74 million drawn as of March 30, 2018, (ii) a $328 million term loan A facility (the “TLA Facility”), and (iii) an $830 million term loan B facility (the “TLB Facility”). Additionally, as of March 30, 2018, we had $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”) outstanding. The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio (as defined in the agreement governing the Senior Secured Credit Facilities) of 6.0:1.0, subject to periodic step downs beginning in the third fiscal quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 2.75:1.0 subject to a step up beginning in the first quarter of 2019. As of March 30, 2018, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 4.9 to 1.00. For the twelve month period ended March 30, 2018, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.4 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of March 30, 2018, we were in full compliance with the financial covenants described above. However, a significant increase in the LIBOR interest rate and/or a decline in our operating performance, and in particular our sales and/or adjusted EBITDA, could result in our inability to meet these financial covenants and lead to an event of default if a waiver or amendment could not be obtained from our lenders.

The Revolving Credit Facility is supported by a consortium of thirteen lenders with no lender controlling more than 27% of the facility. As of March 30, 2018, the banks supporting the majority of the Revolving Credit Facility had an S&P credit rating of at least BBB+ or better, which is considered investment grade. The banks supporting the remaining Revolving Credit Facility are not currently being rated.

See Note 4 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description on the Company’s outstanding debt.

***Non-Guarantor Information –*** For the quarter ended March 30, 2018, our subsidiaries that are non-Guarantors under our Senior Secured Credit Facilities represented approximately 40% and 49% of our revenue and EBITDA, respectively. In addition, as of March 30, 2018, the non-Guarantors under our Senior Secured Credit Facilities held approximately 32% of our total tangible assets and 5% of our total tangible liabilities. Tangible assets consist of total assets less intangible assets, intercompany receivables, and deferred taxes. Tangible liabilities consist of total liabilities less intercompany payables and deferred taxes.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 15 “Impact of Recently Issued Accounting Standards” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

- 37 -

### Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended March 30, 2018 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 29, 2017. See Note 4 “Debt” and Note 9 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 29, 2017.

- 38 -

## Market risk

As filed, 541 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,413 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of March 30, 2018. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of March 30, 2018, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 39 -

## Risk factors

As filed, 171 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.

Filed May 4, 2018.
Source: SEC EDGAR, the filing index for accession 0001114483-18-000014. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
